Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134042 · ClinicalTrials.gov registry record · Phase 3
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT01134042 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 587 participants.
The verdict
NCT01134042, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.
Interventions
- DRUG Fluticasone Furoate/Vilanterol Inhalation Powder
- DRUG Fluticasone Furoate Inhalation Powder
- DRUG Fluticasone Propionate Inhalation Powder
- OTHER Placebo Inhalation Powder 1
- OTHER Placebo Inhalation Powder 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134042
The ClinicalTrials.gov registry entry for NCT01134042 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluticasone Furoate/Vilanterol Inhalation Powder is the first listed.
NCT01134042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134042 about?
NCT01134042 is a clinical study titled "Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics". The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age an...
What is the current status of trial NCT01134042?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2010-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01134042?
The interventions under investigation include: Fluticasone Furoate/Vilanterol Inhalation Powder (DRUG), Fluticasone Furoate Inhalation Powder (DRUG), Fluticasone Propionate Inhalation Powder (DRUG), Placebo Inhalation Powder 1 (OTHER), Placebo Inhalation Powder 2 (OTHER).
Who is sponsoring clinical trial NCT01134042?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.